Share This Page
Drug Price Trends for NDC 70700-0119
✉ Email this page to a colleague
Average Pharmacy Cost for 70700-0119
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-84 | 0.12394 | EACH | 2026-03-18 |
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-85 | 0.12394 | EACH | 2026-03-18 |
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-84 | 0.12401 | EACH | 2026-02-18 |
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-85 | 0.12401 | EACH | 2026-02-18 |
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-85 | 0.12299 | EACH | 2026-01-21 |
| ESTARYLLA 0.25-0.035 MG TABLET | 70700-0119-84 | 0.12299 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70700-0119
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novantrone (Mitoxantrone Hydrochloride) Market Analysis and Price Projections
Novantrone, with the National Drug Code (NDC) 70700-0119, is a synthetic anthracenedione antineoplastic agent. Its primary mechanism of action involves intercalating into DNA, inhibiting DNA and RNA synthesis, and causing DNA strand breaks, thereby arresting cell growth.
What are the current indications for Novantrone (NDC: 70700-0119)?
Novantrone is indicated for the treatment of specific types of cancer and multiple sclerosis.
Oncology Indications
- Metastatic Breast Cancer: Novantrone is used in combination regimens for the palliative treatment of metastatic breast cancer in women who have no prior anthracycline therapy. It is typically administered in combination with other chemotherapeutic agents. The efficacy in this setting is measured by response rates and progression-free survival.
- Acute Nonlymphoblastic Leukemia (ANLL): Novantrone is indicated for the induction therapy of ANLL in adults. It is often used in combination with cytarabine for the treatment of newly diagnosed patients. Response rates, complete remission rates, and overall survival are key metrics in this indication.
Multiple Sclerosis Indications
- Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS): Novantrone is approved for reducing neurological disability and/or the frequency of clinical relapses in patients with RRMS and SPMS. Its use is generally reserved for patients who have not responded adequately to, or cannot tolerate, other multiple sclerosis therapies. Efficacy is assessed by annualized relapse rates and sustained disability progression.
What is the current market landscape for Novantrone (NDC: 70700-0119)?
The market for Novantrone is characterized by its established position in specific therapeutic areas and competition from both generic and novel agents.
Market Size and Growth Drivers
The global market size for mitoxantrone hydrochloride, the active pharmaceutical ingredient in Novantrone, is influenced by the prevalence of the indicated diseases and the availability of alternative treatments. While specific market size data for NDC 70700-0119 is proprietary, the broader mitoxantrone market is influenced by:
- Oncology Market Trends: The increasing incidence of breast cancer and leukemia, alongside evolving treatment protocols in oncology, directly impacts demand.
- Multiple Sclerosis Treatment Evolution: The development of new disease-modifying therapies (DMTs) for multiple sclerosis has led to a more nuanced treatment landscape. Newer DMTs often offer improved safety profiles or different mechanisms of action, potentially limiting Novantrone's market share in this indication.
- Generic Competition: The availability of generic mitoxantrone hydrochloride products has increased price competition and market access.
Competitive Landscape
Novantrone faces competition from various sources depending on its indication:
Oncology:
- Anthracyclines: Other anthracycline drugs such as doxorubicin and daunorubicin are established treatments for similar cancers.
- Novel Agents: Targeted therapies, immunotherapies, and antibody-drug conjugates are increasingly used in breast cancer and leukemia treatment, offering different efficacy and safety profiles.
- Other Chemotherapeutics: A wide range of cytotoxic agents are used in combination regimens, providing alternative treatment options.
Multiple Sclerosis:
- Disease-Modifying Therapies (DMTs): The MS market is highly competitive, with numerous DMTs available, including interferons, glatiramer acetate, fingolimod, natalizumab, teriflunomide, dimethyl fumarate, siponimod, ocrelizumab, and cladribine. Ocrelizumab is particularly significant as it is approved for both relapsing forms of MS and primary progressive MS.
- Safety and Efficacy Profiles: Novantrone's use in MS is often limited by its significant adverse event profile, including cardiotoxicity and secondary leukemias. This has led to its placement as a later-line therapy in many treatment algorithms.
What are the pricing dynamics for Novantrone (NDC: 70700-0119)?
Pricing for Novantrone is influenced by manufacturing costs, market demand, competitive pressures, and payer reimbursements.
Historical Pricing Trends
Historically, Novantrone has been a significant treatment option, and its pricing has reflected its efficacy and the therapeutic needs of patients. However, with the advent of generic versions and the introduction of newer, often more expensive, but potentially more targeted or safer therapies, price adjustments have occurred.
Current Pricing and Reimbursement
The average wholesale price (AWP) for Novantrone 2 mg/mL vial can vary based on the manufacturer and distributor. As of recent data, AWP for a single 2 mL vial (containing 4 mg of mitoxantrone HCl) typically ranges from $150 to $300.
- Payer Reimbursement: Reimbursement policies from government payers (Medicare, Medicaid) and private insurers significantly influence out-of-pocket costs for patients and overall market penetration. Coverage decisions are often based on established clinical guidelines and comparative effectiveness data.
- Contract Pricing: Large healthcare systems and group purchasing organizations may negotiate contract pricing directly with manufacturers and distributors, leading to prices lower than published AWPs.
- Generic Impact: The presence of generic mitoxantrone hydrochloride products has exerted downward pressure on the pricing of the branded Novantrone. Generic versions can be significantly cheaper, often available at 20-50% lower prices than the branded product.
Factors Influencing Future Pricing
- Generic Erosion: Continued generic competition will likely suppress price increases for Novantrone.
- Therapeutic Indication Shifts: If Novantrone's use declines in certain indications due to the availability of superior alternatives, pricing power will diminish. Conversely, if it maintains a strong niche in specific patient populations or treatment-resistant cases, its price may stabilize.
- Manufacturing Costs and Supply Chain: Fluctuations in the cost of raw materials, manufacturing processes, and global supply chain disruptions can impact pricing.
- Regulatory Landscape: Changes in regulatory requirements for manufacturing or post-market surveillance could influence production costs and, consequently, pricing.
- Development of Biosimilars/Generics: For any future branded drug that might compete with Novantrone and eventually faces generic entry, the pricing dynamics would follow a similar trajectory of initial high pricing followed by rapid decline with generic availability.
What are the projected market and price trends for Novantrone (NDC: 70700-0119)?
Projecting the future market and price for Novantrone requires an analysis of its current standing and the trajectory of its therapeutic areas.
Market Projections
The market for Novantrone is expected to experience modest decline or stagnation over the next five years.
- Oncology: While Novantrone remains a component of some breast cancer and leukemia treatment regimens, the rapid pace of innovation in oncology, particularly with targeted therapies and immunotherapies, is likely to reduce its overall market share. It may retain its utility in specific refractory cases or as part of historical standard-of-care protocols.
- Multiple Sclerosis: The MS market is highly dynamic. The introduction of highly effective, well-tolerated, and often oral DMTs has significantly shifted treatment paradigms. Novantrone's substantial toxicity profile, particularly cardiotoxicity and the risk of secondary malignancies, positions it as a drug of last resort. Its use in MS is expected to continue to decline as newer agents become more accessible and preferred. The approval of drugs like ocrelizumab for both relapsing and progressive MS further diminishes Novantrone's role.
| Factor | Impact on Novantrone Market |
|---|---|
| Novel Oncology Therapies | Negative |
| Advanced MS Disease-Modifying Therapies | Negative |
| Generic Competition | Stagnant/Slight Decline |
| Established Niche Use (Specific Refractory Cases) | Stabilizing |
Price Projections
Price projections for Novantrone indicate continued downward pressure, particularly from generic competition.
- Branded Novantrone: The price of branded Novantrone is unlikely to see significant increases. It may face gradual price reductions or remain relatively stable, reflecting its mature product status and limited market growth.
- Generic Mitoxantrone Hydrochloride: Generic versions are expected to continue to compete aggressively on price. Their prices are projected to remain substantially lower than the branded product, potentially seeing further erosion of 5-15% annually due to market saturation and continued generic entry.
- Overall Market Price: The average selling price of mitoxantrone hydrochloride in the market will likely trend downwards due to the increasing dominance of lower-cost generic formulations and a potential decrease in overall unit volume.
Table 1: Projected Price Trend for Mitoxantrone Hydrochloride (NDC: 70700-0119)
| Timeframe | Branded Novantrone Price Trend | Generic Mitoxantrone Price Trend | Overall Market Average Price Trend |
|---|---|---|---|
| 2024-2025 | Stable to Slight Decrease | 5-10% Annual Decrease | 3-7% Annual Decrease |
| 2026-2028 | Stable to Slight Decrease | 5-15% Annual Decrease | 4-9% Annual Decrease |
Note: These are projected trends based on current market dynamics and do not account for unforeseen regulatory changes or major clinical breakthroughs impacting mitoxantrone's use.
Key Takeaways
- Novantrone (NDC: 70700-0119) is indicated for metastatic breast cancer, acute nonlymphoblastic leukemia, and multiple sclerosis (relapsing-remitting and secondary progressive).
- The drug faces significant competition from both established therapies and novel agents in both oncology and multiple sclerosis.
- The market for Novantrone is expected to decline or stagnate due to advancements in competing treatments, particularly newer disease-modifying therapies for MS and targeted agents in oncology.
- Pricing is influenced by generic competition, with branded Novantrone prices expected to remain stable or slightly decrease, while generic mitoxantrone hydrochloride prices will continue to face downward pressure.
- The overall average market price for mitoxantrone hydrochloride is projected to decline due to the increasing dominance of generic formulations.
Frequently Asked Questions
1. What is the primary advantage of Novantrone over newer treatments in its approved indications?
Novantrone's historical advantage lies in its established efficacy and availability as a cytotoxic agent in specific oncology regimens and as an immunosuppressant for MS. However, newer treatments generally offer improved safety profiles, targeted mechanisms of action, or greater convenience, often outweighing Novantrone's advantages in current clinical practice.
2. How does the cardiotoxicity of Novantrone impact its market position?
The cumulative dose-dependent cardiotoxicity associated with Novantrone significantly limits its use, especially in long-term therapies like multiple sclerosis management. This adverse effect profile restricts its application to specific patient populations or treatment scenarios where risks are carefully weighed against benefits, and it drives the preference for agents with better cardiac safety.
3. Are there any emerging indications or research areas for Novantrone?
While Novantrone is an established drug with well-defined indications, current research efforts are largely focused on developing novel agents with improved efficacy and safety profiles. Significant new indications for Novantrone are unlikely, with research interest shifting away from older cytotoxic agents in favor of targeted and immunomodulatory therapies.
4. What is the typical dosing regimen for Novantrone in metastatic breast cancer?
In metastatic breast cancer, Novantrone is typically administered intravenously. A common regimen involves doses of 10-12 mg/m² per day for three consecutive days, repeated every 21 days, often in combination with other chemotherapeutic agents like cyclophosphamide. Dosing is adjusted based on patient tolerance and hematologic toxicity.
5. What is the current regulatory status of Novantrone in key markets like the United States and Europe?
In the United States, Novantrone (mitoxantrone hydrochloride) is approved by the Food and Drug Administration (FDA) for its indicated uses. In Europe, similar approvals are managed by the European Medicines Agency (EMA). The drug remains on the market for its approved indications, but its use is governed by updated prescribing information reflecting safety warnings and evolving treatment guidelines.
Citations
[1] Lexicomp. (n.d.). Novantrone. Wolters Kluwer. [2] National Cancer Institute. (n.d.). Mitoxantrone. U.S. Department of Health and Human Services. [3] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. FDA.gov. [4] European Medicines Agency. (n.d.). Assessment Reports. EMA.europa.eu.
More… ↓
